These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9266421)

  • 1. Role of interferons in demyelinating diseases.
    Arnason BG; Toscas A; Dayal A; Qu Z; Noronha A
    J Neural Transm Suppl; 1997; 49():117-23. PubMed ID: 9266421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interferons in demyelinating disease.
    Johnson KP
    J Neural Transm Suppl; 1997; 49():111-5. PubMed ID: 9266420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis.
    Wang X; Chen M; Wandinger KP; Williams G; Dhib-Jalbut S
    J Immunol; 2000 Jul; 165(1):548-57. PubMed ID: 10861095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta in multiple sclerosis.
    Arnason BG
    Clin Immunol Immunopathol; 1996 Oct; 81(1):1-11. PubMed ID: 8808634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis.
    Bakhiet M; Ozenci V; Withagen C; Mustafa M; Fredrikson S; Link H
    Clin Diagn Lab Immunol; 1999 May; 6(3):415-9. PubMed ID: 10225846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
    Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of interferons in the treatment of multiple sclerosis.
    Kelley CL
    J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 14. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion.
    Dhib-Jalbut S; Jiang H; Williams GJ
    J Neuroimmunol; 1996 Dec; 71(1-2):215-22. PubMed ID: 8982122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of interferon beta-1b on cytokine-induced adhesion molecule expression.
    Jiang H; Williams GJ; Dhib-Jalbut S
    Neurochem Int; 1997; 30(4-5):449-53. PubMed ID: 9106260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferons in multiple sclerosis. A review of the evidence.
    Panitch HS
    Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
    Feng X; Petraglia AL; Chen M; Byskosh PV; Boos MD; Reder AT
    J Neuroimmunol; 2002 Aug; 129(1-2):205-15. PubMed ID: 12161037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.